Clinical Trials in Valencia, Valencia
3 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Not Applicable
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Lung Cancer (Diagnosis)Health Adult SubjectsPatient
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)1,200 enrolled12 locationsNCT07465848
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 3
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos120 enrolled27 locationsNCT05918302
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Pathological Response After Neoadjuvant Treatment on NSCLC
Stage IIIA Non-small Cell Lung Cancer
Fundación GECP150 enrolled17 locationsNCT05167487
Recruiting
Phase 2
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP37 enrolled20 locationsNCT07242547
Recruiting
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Fundación GECP50 enrolled22 locationsNCT06634199
Recruiting
Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Amgen220 enrolled30 locationsNCT06598306
Recruiting
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Fundación GECP97 enrolled21 locationsNCT07153445
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
SCLC
Zai Lab (Shanghai) Co., Ltd.112 enrolled38 locationsNCT06179069
Recruiting
The Impact of Radiotherapy on Oligometastatic Cancer
Metastatic Breast CancerMetastatic Lung CancerMetastasis+2 more
Institut Investigacio Sanitaria Pere Virgili2,000 enrolled21 locationsNCT05933876
Recruiting
Not Applicable
Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study
Breast Cancer FemaleCardiometabolic SyndromeMetabolism Disorder, Lipid+2 more
University of Valencia56 enrolled1 locationNCT06336070